BIOMAT Database Logo BIOMAT Database Logo

[Effectiveness of anti-arrhythmia agents in atrial fibrillation paroxysms]. 1980

Iu V Anshelevich, and T A Sorokina, and F A Bekere, and A K Slaĭdyn', and E T Beer

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004418 Dyspnea, Paroxysmal A disorder characterized by sudden attacks of respiratory distress in at rest patients with HEART FAILURE and PULMONARY EDEMA. It usually occurs at night after several hours of sleep in a reclining position. Patients awaken with a feeling of suffocation, coughing, a cold sweat, and TACHYCARDIA. When there is significant WHEEZING, it is called CARDIAC ASTHMA. Asthma, Cardiac,Paroxysmal Nocturnal Dyspnea,Dyspnea, Paroxysmal Nocturnal,Cardiac Asthma,Cardiac Asthmas,Nocturnal Dyspnea, Paroxysmal,Paroxysmal Dyspnea
D004554 Electric Countershock An electrical current applied to the HEART to terminate a CARDIAC ARRHYTHMIA. Cardiac Electroversion,Cardioversion,Defibrillation, Electric,Electroversion, Cardiac,Electrical Cardioversion,Electroversion Therapy,Therapy, Electroversion,Cardiac Electroversions,Cardioversion, Electrical,Cardioversions,Cardioversions, Electrical,Countershock, Electric,Countershocks, Electric,Defibrillations, Electric,Electric Countershocks,Electric Defibrillation,Electric Defibrillations,Electrical Cardioversions,Electroversion Therapies,Electroversions, Cardiac,Therapies, Electroversion
D004630 Emergencies Situations or conditions requiring immediate intervention to avoid serious adverse results. Emergency
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000889 Anti-Arrhythmia Agents Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. Anti-Arrhythmia Agent,Anti-Arrhythmia Drug,Anti-Arrhythmic,Antiarrhythmia Agent,Antiarrhythmia Drug,Antiarrhythmic Drug,Antifibrillatory Agent,Antifibrillatory Agents,Cardiac Depressant,Cardiac Depressants,Myocardial Depressant,Myocardial Depressants,Anti-Arrhythmia Drugs,Anti-Arrhythmics,Antiarrhythmia Agents,Antiarrhythmia Drugs,Antiarrhythmic Drugs,Agent, Anti-Arrhythmia,Agent, Antiarrhythmia,Agent, Antifibrillatory,Agents, Anti-Arrhythmia,Agents, Antiarrhythmia,Agents, Antifibrillatory,Anti Arrhythmia Agent,Anti Arrhythmia Agents,Anti Arrhythmia Drug,Anti Arrhythmia Drugs,Anti Arrhythmic,Anti Arrhythmics,Depressant, Cardiac,Depressant, Myocardial,Depressants, Cardiac,Depressants, Myocardial,Drug, Anti-Arrhythmia,Drug, Antiarrhythmia,Drug, Antiarrhythmic,Drugs, Anti-Arrhythmia,Drugs, Antiarrhythmia,Drugs, Antiarrhythmic
D001281 Atrial Fibrillation Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation. Auricular Fibrillation,Familial Atrial Fibrillation,Paroxysmal Atrial Fibrillation,Persistent Atrial Fibrillation,Atrial Fibrillation, Familial,Atrial Fibrillation, Paroxysmal,Atrial Fibrillation, Persistent,Atrial Fibrillations,Atrial Fibrillations, Familial,Atrial Fibrillations, Paroxysmal,Atrial Fibrillations, Persistent,Auricular Fibrillations,Familial Atrial Fibrillations,Fibrillation, Atrial,Fibrillation, Auricular,Fibrillation, Familial Atrial,Fibrillation, Paroxysmal Atrial,Fibrillation, Persistent Atrial,Fibrillations, Atrial,Fibrillations, Auricular,Fibrillations, Familial Atrial,Fibrillations, Paroxysmal Atrial,Fibrillations, Persistent Atrial,Paroxysmal Atrial Fibrillations,Persistent Atrial Fibrillations

Related Publications

Iu V Anshelevich, and T A Sorokina, and F A Bekere, and A K Slaĭdyn', and E T Beer
[Therapy of atrial fibrillation with class III anti-arrhythmia agents].
February 1993, Herz,
Iu V Anshelevich, and T A Sorokina, and F A Bekere, and A K Slaĭdyn', and E T Beer
[Comparative effectiveness of treating paroxysms of atrial fibrillation and flutter].
October 1980, Kardiologiia,
Iu V Anshelevich, and T A Sorokina, and F A Bekere, and A K Slaĭdyn', and E T Beer
[Atrial fibrillation paroxysms associated with complete arrhythmia, without other signs of heart disease].
September 1972, Vojnosanitetski pregled,
Iu V Anshelevich, and T A Sorokina, and F A Bekere, and A K Slaĭdyn', and E T Beer
[Evaluation of the anti-arrhythmia effectiveness of Phenazolinum Polfa in paroxysmal atrial fibrillation].
January 1990, Polski tygodnik lekarski (Warsaw, Poland : 1960),
Iu V Anshelevich, and T A Sorokina, and F A Bekere, and A K Slaĭdyn', and E T Beer
[Anti-arrhythmia agents. Effectiveness, lack of effectiveness and pro-arrhythmia effects].
October 1992, Der Internist,
Iu V Anshelevich, and T A Sorokina, and F A Bekere, and A K Slaĭdyn', and E T Beer
[Innovations in anti-arrhythmia therapy of atrial fibrillation].
December 2010, Herzschrittmachertherapie & Elektrophysiologie,
Iu V Anshelevich, and T A Sorokina, and F A Bekere, and A K Slaĭdyn', and E T Beer
[Use of trans-esophageal cardiac electric stimulation in the evaluation of anti-arrhythmia therapy in patients with paroxysms of atrial fibrillation and atrial flutter].
July 1990, Kardiologiia,
Iu V Anshelevich, and T A Sorokina, and F A Bekere, and A K Slaĭdyn', and E T Beer
[Problems with anti-arrhythmia therapy in atrial fibrillation].
January 1994, Zeitschrift fur Kardiologie,
Iu V Anshelevich, and T A Sorokina, and F A Bekere, and A K Slaĭdyn', and E T Beer
[Clinical effectiveness of cordarone in combination with other anti-arrhythmia agents in refractory atrial fibrillation and adverse effects of the drugs].
June 1992, Kardiologiia,
Iu V Anshelevich, and T A Sorokina, and F A Bekere, and A K Slaĭdyn', and E T Beer
[Therapy of paroxysmal atrial fibrillation. Cardiac glycosides alone or combined with anti-arrhythmia agents?].
December 1988, Deutsche medizinische Wochenschrift (1946),
Copied contents to your clipboard!